Developer docs
API playgroundTry for free, no card

Search company profiles

ZEISS Medical Technology

Full company profile

uuid002rph5

Namestring
ZEISS Medical Technology
Legal namestring
Carl Zeiss AG
Websiteurl
zeiss.com
Company typeenum
Private
Founded yearint
1846
Descriptiontext

ZEISS Medical Technology is a segment of the ZEISS Group that develops and manufactures optical and imaging technologies for ophthalmology and microsurgery. The portfolio includes surgical microscopes, femtosecond laser systems (VISUMAX) used for minimally invasive refractive procedures (SMILE), optical biometry systems (IOLMaster), and ultra-widefield retinal imaging systems (CLARUS). The segment operates through Carl Zeiss Meditec AG, a publicly listed subsidiary on the Frankfurt Stock Exchange (ticker: AFX), and serves eye care professionals, hospitals, and microsurgery centers globally. ZEISS Medical Technology builds on the parent ZEISS Group's 175+ year heritage in optics and photonics and is supported by the group's broader R&D investment of approximately EUR 1.7+ billion annually (roughly 15% of group revenue).

The segment generates revenue primarily through direct enterprise sales of hardware-based capital equipment to hospitals, eye clinics, and microsurgery centers, supported by software, service, and consumables. Go-to-market is executed through a global network of over 60 sales and service sites across approximately 50 countries, employing a consultative field-sales model suited to complex medical devices that require clinical evaluation, installation, training, and ongoing service. The Medical Technology segment generated EUR 2.704 billion in fiscal year 2024/25, a 4% year-over-year increase (6% adjusted for currency effects) versus EUR 2.611 billion in fiscal year 2023/24.

The ZEISS Group is wholly owned by the Carl Zeiss Foundation, established in 1889 by Ernst Abbe, one of the oldest company-affiliated foundations in Germany and explicitly prohibited from selling its ZEISS shares. This ownership structure provides long-term orientation and stable funding for R&D, while Carl Zeiss Meditec AG remains publicly traded as the listed medical technology entity. The segment competes across two primary verticals: ophthalmology (cataract, refractive, retinal, and glaucoma diagnostics and treatment) and microsurgery (neurosurgery visualization, oncology, and precision surgical interventions).

Short descriptiontext

ZEISS Medical Technology is a segment of the ZEISS Group that develops optical and imaging systems for ophthalmology and microsurgery, including surgical microscopes, the VISUMAX refractive laser, and the SMILE procedure, sold to hospitals, eye clinics, and surgical centers globally through direct enterprise sales.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
5,001–10,000
akta.pro rankint
HeadquartersJena, Germany
HQ citystring
Jena
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ophthalmic surgical equipment, medical imaging devices, refractive surgery systems, surgical microscopy solutions, diagnostic imaging systems
Industry2 codes
PRIMARYHLAKAKAF
Cornea, External Disease & Refractive Surgery (LASIK/PRK)
SECONDARYHLAHAJAB
Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Ophthalmic Medical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Technology Segment Revenue
TypeHardware Sales
Description

ZEISS Medical Technology generates revenue through the sale of medical devices and solutions for ophthalmology and microsurgery. Revenue is reported as a segment of the ZEISS Group, with the segment achieving EUR 2.704 billion in fiscal year 2024/25, a 4% year-over-year increase (6% adjusted for currency effects). The segment's revenue model is primarily hardware-driven with associated software, service, and consumables.

zeiss.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1ZEISS SMILE
Description

Minimally invasive lenticule extraction technology for vision correction using VISUMAX laser system.

zeiss.com
+3 more records
Core offering1 text field

ZEISS Medical Technology develops, manufactures, and sells optical, laser, and imaging medical devices for ophthalmology and microsurgery. Core offerings include the VISUMAX femtosecond laser system that enables the SMILE minimally invasive refractive surgery procedure, surgical microscopes for neurosurgery and oncology, and AI-integrated diagnostic imaging systems such as the IOLMaster optical biometry platform and CLARUS ultra-widefield retinal imager. The segment sells these products primarily through enterprise field sales to hospitals, eye clinics, and microsurgery centers worldwide.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Medical Technology segment revenue of EUR 2.704 billion in FY 2024/25, growing 4% (6% currency-adjusted) year-over-year
+2 more records
Product overview1 text field

ZEISS Medical Technology is a segment of the ZEISS Group focused on ophthalmology and microsurgery solutions. The portfolio includes VISUMAX laser systems for refractive surgery and SMILE procedures, which work together to enable minimally invasive vision correction treatments. The segment aims to shape medical progress in ophthalmology and microsurgery, helping medical professionals enhance patients' quality of life.

Product and service3 records
1VISUMAX
CategoryRefractive surgery laser systems
2SMILE
CategoryRefractive surgery procedures
3IOLMaster
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1LG Chem
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-10-29
Description

ZEISS and LG Chem established a strategic partnership to supply photopolymer films for automotive holographic windshield displays, with production targeted for 2029. The alliance aims to strengthen supply chain resilience and support growth in holography and optical technologies in mobility and other sectors. This partnership extends ZEISS's optical technology into the automotive augmented reality display market.

prnewswire.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

HOYA Vision Care is a major competitor in intraocular lenses and ophthalmic optics, with broader operations in electronics and imaging. Its IOL business is directly comparable to ZEISS Medical Technology's cataract surgery ecosystem.

TypeEmerging player
Description

STAAR Surgical specializes in Implantable Collamer Lenses (ICL) for refractive vision correction, representing an alternative to ZEISS's SMILE/VISUMAX-based corneal refractive surgery. It is a more focused, smaller competitor addressing the same underlying demand for premium vision correction.

TypeBroad incumbent
Description

Olympus competes with ZEISS Medical Technology in surgical visualization and microscopes for microsurgery and is a broader medtech incumbent with deep hospital channel relationships that overlap with ZEISS's microsurgery centers.

TypeDirect peer
Description

Alcon is the largest pure-play ophthalmology company globally, competing head-to-head with ZEISS Medical Technology across cataract surgical devices, refractive surgery lasers (e.g., WaveLight), and intraocular lenses. It is the most direct competitor in premium ophthalmic surgical platforms.

TypeDirect peer
Description

Heidelberg Engineering specializes in OCT, confocal microscopy, and retinal imaging systems, competing with ZEISS Medical Technology's OCT and ultra-widefield retinal imaging products in specialty ophthalmology practices.

TypeBroad incumbent
Description

Leica Microsystems, owned by Danaher, competes with ZEISS Medical Technology in surgical microscopes for neurosurgery and oncology. It is part of a much larger life sciences and diagnostics platform, giving it broader resources than ZEISS's standalone microsurgery offering.

TypeDirect peer
Description

Nidek is a Japanese ophthalmic equipment manufacturer offering refractive surgery lasers, diagnostic devices, and surgical systems, with particular strength in refractive and cataract surgery markets that overlap with ZEISS Medical Technology's VISUMAX portfolio.

8Topcon Corporation
TypeDirect peer
Description

Topcon is a leading Japanese manufacturer of ophthalmic diagnostic equipment (OCT, fundus cameras, refractors) and surgical solutions, competing directly with ZEISS's diagnostic imaging portfolio including CLARUS and IOLMaster-class products.

TypeDirect peer
Description

Johnson & Johnson Vision (part of J&J MedTech) competes directly with ZEISS Medical Technology across cataract surgery, refractive surgery (including its LASIK platform), and contact lens/ocular surface products, with comparable global commercial scale.

TypeDirect peer
Description

Bausch + Lomb is a major competitor in cataract surgery equipment, intraocular lenses, and ophthalmic surgical instrumentation, with global reach that overlaps with ZEISS Medical Technology's installed base in eye clinics and hospitals.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ZEISS Medical Technology

Ophthalmic Medical Deviceszeiss.com

ZEISS Medical Technology is a segment of the ZEISS Group that develops optical and imaging systems for ophthalmology and microsurgery, including surgical microscopes, the VISUMAX refractive laser, and the SMILE procedure, sold to hospitals, eye clinics, and surgical centers globally through direct enterprise sales.

What ZEISS Medical Technology does

ZEISS Medical Technology is a segment of the ZEISS Group that develops and manufactures optical and imaging technologies for ophthalmology and microsurgery. The portfolio includes surgical microscopes, femtosecond laser systems (VISUMAX) used for minimally invasive refractive procedures (SMILE), optical biometry systems (IOLMaster), and ultra-widefield retinal imaging systems (CLARUS). The segment operates through Carl Zeiss Meditec AG, a publicly listed subsidiary on the Frankfurt Stock Exchange (ticker: AFX), and serves eye care professionals, hospitals, and microsurgery centers globally. ZEISS Medical Technology builds on the parent ZEISS Group's 175+ year heritage in optics and photonics and is supported by the group's broader R&D investment of approximately EUR 1.7+ billion annually (roughly 15% of group revenue).

The segment generates revenue primarily through direct enterprise sales of hardware-based capital equipment to hospitals, eye clinics, and microsurgery centers, supported by software, service, and consumables. Go-to-market is executed through a global network of over 60 sales and service sites across approximately 50 countries, employing a consultative field-sales model suited to complex medical devices that require clinical evaluation, installation, training, and ongoing service. The Medical Technology segment generated EUR 2.704 billion in fiscal year 2024/25, a 4% year-over-year increase (6% adjusted for currency effects) versus EUR 2.611 billion in fiscal year 2023/24.

The ZEISS Group is wholly owned by the Carl Zeiss Foundation, established in 1889 by Ernst Abbe, one of the oldest company-affiliated foundations in Germany and explicitly prohibited from selling its ZEISS shares. This ownership structure provides long-term orientation and stable funding for R&D, while Carl Zeiss Meditec AG remains publicly traded as the listed medical technology entity. The segment competes across two primary verticals: ophthalmology (cataract, refractive, retinal, and glaucoma diagnostics and treatment) and microsurgery (neurosurgery visualization, oncology, and precision surgical interventions).

ZEISS Medical Technology firmographics

Firmographics
Name
ZEISS Medical Technology
Legal name
Carl Zeiss AG
Website
https://zeiss.com
Company type
Private
Founded year
1846
Operating status
Operating
Headcount range
5,001–10,000 employees
Short description
ZEISS Medical Technology is a segment of the ZEISS Group that develops optical and imaging systems for ophthalmology and microsurgery, including surgical microscopes, the VISUMAX refractive laser, and the SMILE procedure, sold to hospitals, eye clinics, and surgical centers globally through direct enterprise sales.
Ownership category
akta.pro rank

ZEISS Medical Technology industry classification

Industry
Product category
Ophthalmic Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAKAKAF
Cornea, External Disease & Refractive Surgery (LASIK/PRK)
SECONDARYHLAHAJAB
Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)

Keywords

  • Ophthalmic surgical equipment
  • Medical imaging devices
  • Refractive surgery systems
  • Surgical microscopy solutions
  • Diagnostic imaging systems

Where ZEISS Medical Technology is headquartered

Location

Headquarters

HQ city
Jena
HQ country
Germany
HQ region
Europe

Offices7 records

Markets served

ZEISS Medical Technology business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Technology Segment Revenue: ZEISS Medical Technology generates revenue through the sale of medical devices and solutions for ophthalmology and microsurgery. Revenue is reported as a segment of the ZEISS Group, with the segment achieving EUR 2.704 billion in fiscal year 2024/25, a 4% year-over-year increase (6% adjusted for currency effects). The segment's revenue model is primarily hardware-driven with associated software, service, and consumables.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

ZEISS Medical Technology product offering

Product offering

Core offering

ZEISS Medical Technology develops, manufactures, and sells optical, laser, and imaging medical devices for ophthalmology and microsurgery. Core offerings include the VISUMAX femtosecond laser system that enables the SMILE minimally invasive refractive surgery procedure, surgical microscopes for neurosurgery and oncology, and AI-integrated diagnostic imaging systems such as the IOLMaster optical biometry platform and CLARUS ultra-widefield retinal imager. The segment sells these products primarily through enterprise field sales to hospitals, eye clinics, and microsurgery centers worldwide.

Product overview

ZEISS Medical Technology is a segment of the ZEISS Group focused on ophthalmology and microsurgery solutions. The portfolio includes VISUMAX laser systems for refractive surgery and SMILE procedures, which work together to enable minimally invasive vision correction treatments. The segment aims to shape medical progress in ophthalmology and microsurgery, helping medical professionals enhance patients' quality of life.

Differentiator

Problem solved

Functional benefit

Brands

  • ZEISS SMILE: Minimally invasive lenticule extraction technology for vision correction using VISUMAX laser system.
  • ZEISS VISUMAX
  • ZEISS IOLMaster
  • ZEISS CLARUS

Products and services

  • VISUMAX
  • SMILE
  • IOLMaster

Quantifiable outcome

  • Medical Technology segment revenue of EUR 2.704 billion in FY 2024/25, growing 4% (6% currency-adjusted) year-over-year
  • +2 more outcomes

Companies that use ZEISS Medical Technology

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

ZEISS Medical Technology technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

ZEISS Medical Technology partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • LG ChemstrategicStrategic or Co-development Partner · 29 October 2025ZEISS and LG Chem established a strategic partnership to supply photopolymer films for automotive holographic windshield displays, with production targeted for 2029. The alliance aims to strengthen supply chain resilience and support growth in holography and optical technologies in mobility and other sectors. This partnership extends ZEISS's optical technology into the automotive augmented reality display market.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

ZEISS Medical Technology competitors and assessment

Company assessment

Broad incumbents

  • HOYA Corporation: HOYA Vision Care is a major competitor in intraocular lenses and ophthalmic optics, with broader operations in electronics and imaging. Its IOL business is directly comparable to ZEISS Medical Technology's cataract surgery ecosystem.
  • Olympus Corporation: Olympus competes with ZEISS Medical Technology in surgical visualization and microscopes for microsurgery and is a broader medtech incumbent with deep hospital channel relationships that overlap with ZEISS's microsurgery centers.
  • Leica Microsystems (Danaher): Leica Microsystems, owned by Danaher, competes with ZEISS Medical Technology in surgical microscopes for neurosurgery and oncology. It is part of a much larger life sciences and diagnostics platform, giving it broader resources than ZEISS's standalone microsurgery offering.

Emerging players

  • STAAR Surgical: STAAR Surgical specializes in Implantable Collamer Lenses (ICL) for refractive vision correction, representing an alternative to ZEISS's SMILE/VISUMAX-based corneal refractive surgery. It is a more focused, smaller competitor addressing the same underlying demand for premium vision correction.

Direct peers

  • Alcon: Alcon is the largest pure-play ophthalmology company globally, competing head-to-head with ZEISS Medical Technology across cataract surgical devices, refractive surgery lasers (e.g., WaveLight), and intraocular lenses. It is the most direct competitor in premium ophthalmic surgical platforms.
  • Heidelberg Engineering: Heidelberg Engineering specializes in OCT, confocal microscopy, and retinal imaging systems, competing with ZEISS Medical Technology's OCT and ultra-widefield retinal imaging products in specialty ophthalmology practices.
  • Nidek: Nidek is a Japanese ophthalmic equipment manufacturer offering refractive surgery lasers, diagnostic devices, and surgical systems, with particular strength in refractive and cataract surgery markets that overlap with ZEISS Medical Technology's VISUMAX portfolio.
  • Topcon Corporation: Topcon is a leading Japanese manufacturer of ophthalmic diagnostic equipment (OCT, fundus cameras, refractors) and surgical solutions, competing directly with ZEISS's diagnostic imaging portfolio including CLARUS and IOLMaster-class products.
  • Johnson & Johnson Vision: Johnson & Johnson Vision (part of J&J MedTech) competes directly with ZEISS Medical Technology across cataract surgery, refractive surgery (including its LASIK platform), and contact lens/ocular surface products, with comparable global commercial scale.
  • Bausch + Lomb: Bausch + Lomb is a major competitor in cataract surgery equipment, intraocular lenses, and ophthalmic surgical instrumentation, with global reach that overlaps with ZEISS Medical Technology's installed base in eye clinics and hospitals.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

ZEISS Medical Technology social profiles

Digital presence

ZEISS Medical Technology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ZEISS Medical Technology leadership team

Management profile

Number of profiles

Profiles3 records

ZEISS Medical Technology subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

ZEISS Medical Technology funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ZEISS Medical Technology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ZEISS Medical Technology

What does ZEISS Medical Technology do?

ZEISS Medical Technology develops, manufactures, and sells optical, laser, and imaging medical devices for ophthalmology and microsurgery. Core offerings include the VISUMAX femtosecond laser system that enables the SMILE minimally invasive refractive surgery procedure, surgical microscopes for neurosurgery and oncology, and AI-integrated diagnostic imaging systems such as the IOLMaster optical biometry platform and CLARUS ultra-widefield retinal imager. The segment sells these products primarily through enterprise field sales to hospitals, eye clinics, and microsurgery centers worldwide.

Is ZEISS Medical Technology a public or private company?

ZEISS Medical Technology is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was ZEISS Medical Technology founded?

ZEISS Medical Technology was founded in 1846. It employs 5,001 to 10,000 people.

Where is ZEISS Medical Technology based?

ZEISS Medical Technology is headquartered in Jena, Germany, in the Europe region.

How does ZEISS Medical Technology make money?

One revenue line is on record: medical Technology Segment Revenue.

Who are ZEISS Medical Technology's main competitors?

Broad incumbents on record are HOYA Corporation, Olympus Corporation and Leica Microsystems (Danaher). STAAR Surgical is listed as an emerging player. Direct peers are Alcon, Heidelberg Engineering, Nidek, Topcon Corporation, Johnson & Johnson Vision and Bausch + Lomb.

Does ZEISS Medical Technology have an API?

No public API is recorded for ZEISS Medical Technology.

What industry is ZEISS Medical Technology in?

ZEISS Medical Technology's product category is Ophthalmic Medical Devices. Its primary akta.pro industry code is HLAKAKAF, Cornea, External Disease & Refractive Surgery (LASIK/PRK), with a secondary code of HLAHAJAB, Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR Newswire APACZEISS to expand myopia solutions in China with NMPA's approval of ZEISS PT LUNANA phakic intraocular lensZEISS Medical Technology received NMPA approval for its PT LUNANA phakic intraocular lens in China, marking the first step in its phakic IOL portfolio. The lens, featuring aspheric design and AQUAFLEX material, will be commercialized in China in 2027, with global expansion planned.NewswireZEISS to expand myopia solutions in China with NMPA's approval of ZEISS PT LUNANA phakic intraocular lensZEISS Medical Technology received NMPA approval for its PT LUNANA phakic intraocular lens in China, the first in the PT family. The company plans to commercialize the product in China in 2027, with global rollout following. The lens targets myopic patients, including those with thin corneas or high myopia.AktienZEISS to expand myopia solutions in China with NMPA's approval of ZEISS PT LUNANA phakic intraocular lensZEISS Medical Technology received NMPA approval for its PT LUNANA phakic intraocular lens, the first in the PT family, and showcased it at the CIIE in Shanghai. The lens, developed by a Wuxi joint venture, is set for local manufacturing and release in the coming year.PR NewswireZEISS to expand myopia solutions in China with NMPA's approval of ZEISS PT LUNANA phakic intraocular lensZEISS Medical Technology received NMPA approval for its PT LUNANA phakic intraocular lens, the first in the PT family, and showcased it at the CIIE in Shanghai. The lens is developed by a Chinese joint venture and will be manufactured locally, targeting China's 600 million myopia patients.PR Newswire APACZEISS demonstrates new digital and visual enhancements across ophthalmic workflows at AAOZEISS Medical Technology will showcase digital and visual innovations at the AAO annual meeting in New Orleans, Oct. 10-12. The company reports 15 million eyes treated with SMILE and SMILE pro, and 3 million surgical cases planned with ZEISS VERACITY Surgery Planner. It will also preview the ZEISS MATRIX-VR headset perimeter for glaucoma diagnostics.PR Newswire APACZEISS demonstrates new digital and visual enhancements across ophthalmic workflows at AAOZEISS Medical Technology will showcase digital and visual enhancements at the AAO annual meeting in New Orleans, including the VERACITY Surgery Planner, HMDmd CR3 display, and ATLAS 500 topographer. The company highlights milestones of 3 million surgical cases planned and 15 million eyes treated with SMILE and SMILE pro. It also previews the ZEISS MATRIX-VR headset perimeter for glaucoma screening.YahooFrom diagnosis to treatment, ZEISS introduces innovations across ZEISS Retina Workflow at EURETINA 2026ZEISS Medical Technology unveiled new retinal imaging and surgical innovations at EURETINA 2026, including the ALTA DUO 300 combining OCT and fundus imaging, and the HMDmd CR3 head-mounted display. DORC ILM-BLUE and MEMBRANEBLUE-DUAL dyes reached 3 million cumulative sales, and the DORC brand was unified under ZEISS.PR Newswire APACFrom diagnosis to treatment, ZEISS introduces innovations across ZEISS Retina Workflow at EURETINA 2026ZEISS Medical Technology unveiled new retinal imaging and surgical innovations at EURETINA 2026, including the ALTA DUO 300 combining OCT and fundus imaging, the HMDmd CR3 head-mounted display, and DORC surgical dyes reaching 3 million cumulative sales. The company also unified the DORC brand under ZEISS, aiming to simplify customer relationships.PR NewswireFrom diagnosis to treatment, ZEISS introduces innovations across ZEISS Retina Workflow at EURETINA 2026ZEISS Medical Technology unveiled innovations across its ZEISS Retina Workflow at EURETINA 2026, including the ALTA DUO 300 multimodal imaging device and the HMDmd CR3 head-mounted display. DORC ILM-BLUE and MEMBRANEBLUE-DUAL dyes surpassed 3 million cumulative sales, and the DORC TDC VELOCE cutter offers up to 41% shorter vitrectomy times. ZEISS also announced the DORC brand will be unified under the ZEISS brand.PR NewswireFrom diagnosis to treatment, ZEISS introduces innovations across ZEISS Retina Workflow at EURETINA 2026ZEISS Medical Technology unveiled new retinal imaging and surgical innovations at EURETINA 2026, including the ALTA DUO 300 combining OCT and fundus imaging, and the HMDmd CR3 head-mounted display. The company also highlighted that DORC ILM-BLUE and DORC MEMBRANEBLUE-DUAL dyes reached 3 million procedures, and DORC was integrated under the ZEISS brand.